GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Level Bio AB (XSAT:LEVBIO) » Definitions » Debt-to-EBITDA

Level Bio AB (XSAT:LEVBIO) Debt-to-EBITDA : 0.00 (As of Mar. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Level Bio AB Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Level Bio AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr0.00 Mil. Level Bio AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr0.00 Mil. Level Bio AB's annualized EBITDA for the quarter that ended in Mar. 2024 was kr-7.94 Mil. Level Bio AB's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Level Bio AB's Debt-to-EBITDA or its related term are showing as below:

XSAT:LEVBIO' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -14.26   Med: -0.01   Max: 2.22
Current: -0.12

During the past 13 years, the highest Debt-to-EBITDA Ratio of Level Bio AB was 2.22. The lowest was -14.26. And the median was -0.01.

XSAT:LEVBIO's Debt-to-EBITDA is ranked worse than
100% of 102 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.79 vs XSAT:LEVBIO: -0.12

Level Bio AB Debt-to-EBITDA Historical Data

The historical data trend for Level Bio AB's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Level Bio AB Debt-to-EBITDA Chart

Level Bio AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.80 0.68 0.14 -3.92 -0.15

Level Bio AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - -0.08 -

Competitive Comparison of Level Bio AB's Debt-to-EBITDA

For the Diagnostics & Research subindustry, Level Bio AB's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Level Bio AB's Debt-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Level Bio AB's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Level Bio AB's Debt-to-EBITDA falls into.



Level Bio AB Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Level Bio AB's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.107 + 0) / -7.488
=-0.15

Level Bio AB's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -7.936
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


Level Bio AB  (XSAT:LEVBIO) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Level Bio AB Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Level Bio AB's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Level Bio AB (XSAT:LEVBIO) Business Description

Traded in Other Exchanges
N/A
Address
Vastra Finnbodavagen 4B, Nacka, Stockholm, SWE, 131 30
AlphaHelix Molecular Diagnostics AB develops, manufactures, and markets products for DNA-identification and quantitation in molecular diagnostics and life science research. Its product inlcude Rob, BugScreener MRSA, and aAmp. The company applications inlcude Diagnostics, PCR and Liquid handling.

Level Bio AB (XSAT:LEVBIO) Headlines

No Headlines